Issue 4/2015
Content (15 Articles)
Acknowledgment to Referees
Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agents
Pilar García-Alfonso, Ana Ferrer, Silvia Gil, Rosario Dueñas, María Teresa Pérez, Raquel Molina, Jaume Capdevila, María José Safont, Carmen Castañón, Juana María Cano, Ricardo Lara
Aptamer-Functionalized Nanoparticles as “Smart Bombs”: The Unrealized Potential for Personalized Medicine and Targeted Cancer Treatment
Gregory Benedetto, C. Greer Vestal, Christine Richardson
Renal Toxicities of Targeted Therapies
Anum Abbas, Mohsin M. Mirza, Apar Kishor Ganti, Ketki Tendulkar
Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo
Natalie R. Young, Christian Soneru, Jing Liu, Tatyana A. Grushko, Ashley Hardeman, Olufunmilayo I. Olopade, Anke Baum, Flavio Solca, Ezra E. W. Cohen
Effectiveness and safety of post-induction phase bevacizumab treatment for patients with non-small-cell lung cancer: results from the ARIES observational cohort study
Michael P. Kosty, Antoinette J. Wozniak, Mohammad Jahanzeb, Larry Leon, Susan Fish, Sebastien J. Hazard, Thomas J. Lynch Jr.
Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy
Matteo Santoni, Sebastiano Buti, Alessandro Conti, Camillo Porta, Giuseppe Procopio, Cora N. Sternberg, Sergio Bracarda, Umberto Basso, Ugo De Giorgi, Mimma Rizzo, Lisa Derosa, Cinzia Ortega, Francesco Massari, Michele Milella, Melissa Bersanelli, Linda Cerbone, Giovanni Muzzonigro, Luciano Burattini, Rodolfo Montironi, Daniele Santini, Stefano Cascinu
A rapid screening system evaluates novel inhibitors of DNA methylation and suggests F-box proteins as potential therapeutic targets for high-risk neuroblastoma
Livius Penter, Bert Maier, Ute Frede, Benjamin Hackner, Thomas Carell, Christian Hagemeier, Matthias Truss
Antisense inhibition of microRNA-21 and microRNA-221 in tumor-initiating stem-like cells modulates tumorigenesis, metastasis, and chemotherapy resistance in pancreatic cancer
Yue Zhao, Lu Zhao, Ivan Ischenko, Qi Bao, Bettina Schwarz, Hanno Nieß, Yan Wang, Andrea Renner, Josef Mysliwietz, Karl-Walter Jauch, Peter J. Nelson, Joachim W. Ellwart, Christiane J. Bruns, Peter Camaj
The Association of Serum Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, Thymidine Kinase, and Tissue Polypeptide Specific Antigen with Outcomes of Patients with Metastatic Colorectal Cancer Treated with Bevacizumab: a Retrospective Study
Ondrej Fiala, Jindrich Finek, Tomas Buchler, Vit Martin Matejka, Lubos Holubec, Jana Kulhankova, Zbynek Bortlicek, Vaclav Liska, Ondrej Topolcan
Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study
Katerina Kubackova, Bohuslav Melichar, Zbynek Bortlicek, Tomas Pavlik, Alexandr Poprach, Marek Svoboda, Radek Lakomy, Rostislav Vyzula, Igor Kiss, Ladislav Dusek, Jana Prausova, Tomas Buchler
A combination of the telomerase inhibitor, BIBR1532, and paclitaxel synergistically inhibit cell proliferation in breast cancer cell lines
Yi Shi, Lin Sun, Ge Chen, Dongyan Zheng, Li Li, Wanguo Wei
The Histone Deacetylase Inhibitor Valproic Acid Sensitizes Gemcitabine-Induced Cytotoxicity in Gemcitabine-Resistant Pancreatic Cancer Cells Possibly Through Inhibition of the DNA Repair Protein Gamma-H2AX
Yufeng Wang, Yasuhiro Kuramitsu, Takao Kitagawa, Kazuhiro Tokuda, Byron Baron, Junko Akada, Kazuyuki Nakamura
Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy
Evelyn Despierre, Ignace Vergote, Ryan Anderson, Corneel Coens, Dionyssios Katsaros, Fred R. Hirsch, Bram Boeckx, Marileila Varella-Garcia, Annamaria Ferrero, Isabelle Ray-Coquard, Els M. J. J. Berns, Antonio Casado, Diether Lambrechts, Antonio Jimeno
Detection of KIT and PDGFRA mutations in the plasma of patients with gastrointestinal stromal tumor
Guhyun Kang, Byung Noe Bae, Byeong Seok Sohn, Jung-Soo Pyo, Gu Hyum Kang, Kyoung-Mee Kim